Syndicated Reports

2010 Biosimilar Prescribing Outlook

This study - designed, executed and analyzed by research professionals from the drug development and commercialization industry - sheds light on prescribers' views of biosimilars. It is based on interviews with 264 physicians in the United States and Western Europe.

2010 CRO Quality Benchmarking Report

2011 CRO Quality Benchmarking Report

2012 Benchmarks in Diabetes Management

2012 Medicines in Development for Cancer report

PhRMA’s 2012 Medicines in Development for Cancer report includes information on new oncology drugs in the pipeline and their current development status. The report is broken down by type of cancer and is followed by additional fact sheets and other helpful resources. Our goal is that the report not just serve as an informational resource, but as a source of hope as our sector continues to invest in research for a better future.

2012 Rheumatology Reimbursement Report

Survey Results Identify Key Trends Related to Oral Meds, RA Management, Cost of Therapy, and More

2012-13 Economic Report on Retail, Mail and Specialty Pharmacies

The completely updated, revised, and expanded 2012

2012-13 Economic Report on Retail, Mail and Specialty Pharmacies

For anyone who wants to understand and benefit from the forces reshaping the highly competitive U.S. pharmacy industry, the 2012

2013-14 Economics Report On Retail, Mail, And Specialty Pharmacies

Downloadable PDF By Adam J. Fein, Ph.D.

Are You Managing Your Market Access Team For Success?

ASCO 2014 — Delegate Physicians Rate Influence and Impact

Autoimmune Market Forecast to 2014

Benchmarking the Pharma Industry’s HEOR Functions

This report provides pharmaceutical and biotech organizations an opportunity to benchmark their own Health Economics and Outcomes Research (HEOR) approaches against that of Top 50 Pharma companies. Download Report Preview here. (Source: ISR reports, 2013).

Biosimilar Index: Tracking the Biosimilar Development Landscape

Biosimilars Regulatory Update: an evolving landscape

Biosimilars Report Collection

Biosimilars: Pipeline Trends

Datamonitor has identified a total of 397 biosimilars/copy-biologics across 125 companies as being in development/marked. Products and pipeline candidates were identified using publically available information (where available). For each candidate, the stage of development was determined using company reported information as well as secondary sources such as clinical trial databases.

Biosimilars: Surveying the Market Landscape

Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market

Companion Diagnostics and Biomarker Development

Country report: The healthcare market in South Korea

Country Reports: The healthcare market in Japan

Diabetes Market Forecast to 2015

Generic Pharmaceuticals Market – A Global Analysis

The research report aims to analyze and assess the global generics pharmaceutical market, map the key trends and dynamics shaping the industry sector and provide strategic recommendations for the success of the market participants. With several key blockbuster drugs losing patent protection and new healthcare reforms being introduced by the Governments, the generics pharmaceutical market is on a growing curve. This study provides an in-depth knowledge of the key national markets and therapeutic areas presenting significant growth opportunities for generics, consolidation trends in the industry and impact of regulation on each of the markets.

Guide to Value-Based Reimbursement: Profiting from Payment Bundling, PHO Shared Savings, and Pay for Performance

This Healthcare Intelligence Network (HIN) report, Guide to Value-Based Reimbursement: Profiting from Payment Bundling, PHO Shared Savings, and Pay for Performance, explores emerging models of episode-based payments, physician-hospital organizations and physician bonus structures.

Purchase your copy here.

Health Economics and Outcomes Research

Pricing pressure and regulatory restrictions across various healthcare industries have called for more detailed evidence of outcomes of healthcare products. In order to gain market access, medical technology manufacturers must be able to demonstrate the clinical and economic evidence to providers, healthcare decision-makers and payers to be able to remain competitive.

Health Economics and Outcomes Research

Health Outcomes Liaisons

Health Outcomes Liaisons (HOLs) Serve as Key Bridge between Pharmaceutical Sector and Managed Care Groups

Health Outcomes Liaisons (HOLs) Serve as Key Bridge between Pharmaceutical Sector and Managed Care Groups

Categories

Stay Connected